nabs is a Belgian startup focused on targeted radiotherapy and related treatments. The company recently completed a Series A round that raised nearly $42M. The article places the fundraise amid renewed interest in targeted radiation treatments, noting Novartis’ $2.1 billion bet on Endocyte as a recent example. The report does not disclose product specifics, clinical stage, operating metrics, or the investors in the round. No future plans or financial details beyond the Series A size are provided. The company's location in Belgium is noted in the piece.

Total raised

$42M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2018